Use of a Novel Cell Lysis Buffer for Protection of AAVs and Enhancing Manufacturing Efficiency

Webinar

On demand

Replay

The manufacturing of recombinant adeno-associated virus (rAAV) for use as gene therapies is a complex process that has proven difficult to scale commercially. During manufacturing, intracellular rAAVs are extracted from the host production cells through chemical and/or mechanical lysis. This step presents various challenges in achieving the optimal yield of highly infectious particles. Avantor has developed a novel cell lysis buffer solution with enhanced properties for the manufacturing of rAAVs, which can lead to increased manufacturing efficiency.

In this presentation, we will describe the production and extraction of rAAVs produced in HEK293 cells using this novel cell lysis solution. We will also demonstrate the enhanced protection of the rAAVs against sheer stress when using this cell lysis buffer as compared to traditional methods. Together, the enhanced properties and the ease of use, enable this novel cell lysis buffer to provide a more robust and efficient manufacturing process to produce rAAVs.

This presentation was given during BPI Europe, Vienna, May 17-19, 2022.

Presented by:

 

Dr. Nandu Deorkar, Vice President, Research & Development – Biopharma Production

During his more than 25-year career in materials technology research & development, Dr. Deorkar has worked on various aspects of chemical/polymer R&D, drug development, formulation, drug delivery technologies, process development, and technology transfer. Dr. Deorkar earned his PhD in chemistry from the Indian Institute of Technology, Bombay, and his MBA from Fairleigh Dickinson University, New Jersey (USA).